Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...
You can now be vaccinated against HIV – but that does not mean you can be reckless, warns the Department of Health ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...
The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...
Opinion
A Medical Breakthrough Saved Millions of Lives During COVID. Why Are We Turning Our Backs on It Now?
By Clay Alspach The U.S. government is turning its back on a medical breakthrough that has saved millions of lives, halting $500 million in federal funding to develop new mRNA […] ...
The Department of Health said the decision reflects its mandate to ensure that all citizens have access to safe, effective, ...
Researchers in the TB Alliance informed the Union Conference on Lung Health in Copenhagen that Sorbequiline, a new antibiotic ...
Merck on Wednesday said the Phase 3 study of the once-daily, two-drug single-tablet regimen met the success criterion for its primary efficacy hypothesis, showing non-inferiority to the three-drug ...
Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...
Merck (MRK) stock gains as new oral HIV tablet matches Gilead's (GILD) three-drug once-daily HIV pill Biktarvy in a Phase 3 ...
As of 2024, over 40 million people in the world are diagnosed with human immunodeficiency virus (HIV)-a chronic, life-threatening infection that remains one of the leading global causes of death.
Tatenda Makoni is a Zimbabwean-born medical student at the Medical College of Wisconsin whose work bridges global health and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback